Published in Transplantation on December 15, 1998
Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. Transplantation (2008) 1.62
Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients. Blood (2006) 1.29
Sensitized renal transplant recipients: current protocols and future directions. Nat Rev Nephrol (2010) 0.94
Antibody-mediated rejection of the kidney after simultaneous pancreas-kidney transplantation. J Am Soc Nephrol (2008) 0.80
C4d staining in renal allograft biopsies with early acute rejection and subsequent clinical outcome. Clin J Am Soc Nephrol (2011) 0.80
Late and chronic antibody-mediated rejection: main barrier to long term graft survival. Clin Dev Immunol (2013) 0.79
Benefits and limitations of plasmapheresis in renal diseases: an evidence-based approach. J Artif Organs (2010) 0.78
Rescue therapy with tacrolimus and mycophenolate mofetil does not prevent deterioration of graft function in C4d-positive chronic allograft nephropathy. Wien Klin Wochenschr (2006) 0.77
Antibody-Mediated Rejection: A Review. Ochsner J (2017) 0.75
Clinical strategy for the management of acute humoral rejection in kidney transplantation. Transplantation (1999) 0.75
[Alloantibodies-mediated kidney transplant rejection: a pair of continuing approaches, and with nonetheless many open questions]. Wien Klin Wochenschr (2006) 0.75
Biologics in the prevention and treatment of graft rejection. Springer Semin Immunopathol (2006) 0.75
The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02
Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant (2008) 8.09
Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest (1981) 6.89
Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39
Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest (1996) 3.73
Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med (1981) 3.63
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43
Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant (2006) 3.34
Consensus statement on the live organ donor. JAMA (2000) 3.29
Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29
Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation (1995) 3.18
International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int (1993) 3.11
Report of a National Conference on Donation after cardiac death. Am J Transplant (2006) 3.04
Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol (1983) 2.90
Identification of the CD4(+) T cell as a major pathogenic factor in ischemic acute renal failure. J Clin Invest (2001) 2.79
Role of the clotting system in cell-mediated hypersensitivity. I. Fibrin deposition in delayed skin reactions in man. J Exp Med (1973) 2.75
Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med (2000) 2.61
Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer (1971) 2.56
A study of Complement Fixation in Syphilis with Treponema Antigens. J Med Res (1913) 2.46
Expression of heme oxygenase-1 can determine cardiac xenograft survival. Nat Med (1998) 2.40
Determinants of discard of expanded criteria donor kidneys: impact of biopsy and machine perfusion. Am J Transplant (2008) 2.38
Clonal dominance among T-lymphocyte infiltrates in arthritis. Proc Natl Acad Sci U S A (1988) 2.36
Widespread and selective induction of major histocompatibility complex-determined antigens in vivo by gamma interferon. J Exp Med (1985) 2.34
Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Pathol (1983) 2.33
Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A (1998) 2.29
Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant (2012) 2.28
Antibody to intercellular adhesion molecule 1 protects the kidney against ischemic injury. Proc Natl Acad Sci U S A (1994) 2.26
Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation (1981) 2.22
Guideline for infection control in healthcare personnel, 1998. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol (1998) 2.20
Role of platelet-derived growth factor in wound healing: synergistic effects with other growth factors. Proc Natl Acad Sci U S A (1987) 2.17
A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant (2011) 2.16
Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation (1999) 2.16
Effective treatment of lymphedema of the extremities. Arch Surg (1998) 2.11
Fibronectin and fibrin provide a provisional matrix for epidermal cell migration during wound reepithelialization. J Invest Dermatol (1982) 2.10
Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA (1999) 2.09
Native portal vein embolization for persistent hyperoxaluria following kidney and auxiliary partial liver transplantation. Am J Transplant (2013) 2.05
Growth factors in wound healing. Single and synergistic effects on partial thickness porcine skin wounds. J Clin Invest (1989) 2.04
The immunopathology of experimental allergic encephalomyelitis. II. Endothelial cell Ia increases prior to inflammatory cell infiltration. J Immunol (1984) 2.02
Kidney transplants in mice. An analysis of the immune status of mice bearing long-term, H-2 incompatible transplants. J Exp Med (1978) 1.95
Organ trafficking and transplant tourism: a commentary on the global realities. Am J Transplant (2008) 1.87
Mixed chimerism and tolerance without whole body irradiation in a large animal model. J Clin Invest (2000) 1.86
International practices of organ donation. Br J Anaesth (2012) 1.85
Changing pattern of organ donation at a single center: are potential brain dead donors being lost to donation after cardiac death? Am J Transplant (2010) 1.84
Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections. N Engl J Med (1979) 1.83
Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med (1994) 1.79
Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol (1999) 1.77
Glomerulopathy associated with cytomegalovirus viremia in renal allografts. N Engl J Med (1981) 1.77
BK virus in solid organ transplant recipients: an emerging syndrome. Transplantation (2001) 1.75
Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol (2001) 1.72
Prognostic factors for melanoma patients with lesions 0.76 - 1.69 mm in thickness. An appraisal of "thin" level IV lesions. Ann Surg (1982) 1.72
Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer (1997) 1.71
Morphology of delayed type hypersensitivity reactions in man. I. Quantitative description of the inflammatory response. Lab Invest (1974) 1.68
Pathological and clinical correlates of FOXP3+ cells in renal allografts during acute rejection. Am J Transplant (2007) 1.67
Preliminary description of focal segmental glomerulosclerosis in patients with renovascular disease. Lancet (1996) 1.66
Long-term outcome and alloantibody production in a non-myeloablative regimen for induction of renal allograft tolerance. Transplantation (1999) 1.66
Thymic transplantation in miniature swine. I. Development and function of the "thymokidney". Transplantation (1999) 1.64
Bi-specific monoclonal antibodies: selective binding and complement fixation to cells that express two different surface antigens. J Immunol (1987) 1.64
Depletion of CD8 memory T cells for induction of tolerance of a previously transplanted kidney allograft. Am J Transplant (2007) 1.64
Lymphocyte activation antigens. I. A monoclonal antibody, anti-Act I, defines a new late lymphocyte activation antigen. J Immunol (1984) 1.60
The 'two, one, zero' decision: what to do with suboptimal deceased donor kidneys. Am J Transplant (2010) 1.58
Rubella seropositivity in the United States, 1988-1994. Clin Infect Dis (2001) 1.57
Modulation of surface antigens of a human monocyte cell line, U937, during incubation with T lymphocyte-conditioned medium: detection of T4 antigen and its presence on normal blood monocytes. J Immunol (1983) 1.57
Dynamic challenges inhibiting optimal adoption of kidney paired donation: findings of a consensus conference. Am J Transplant (2013) 1.55
Tolerance in a concordant nonhuman primate model. Transplantation (1999) 1.53
Outcome of kidney transplantation using expanded criteria donors and donation after cardiac death kidneys: realities and costs. Am J Transplant (2007) 1.51
Prevalence of measles antibodies in asymptomatic human immunodeficiency virus-infected adults. J Infect Dis (1991) 1.50
Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression. Am J Transplant (2014) 1.49
Procurement of a whole pancreas and liver from the same cadaveric donor. Surgery (1989) 1.49